ASP 2408

Drug Profile

ASP 2408

Alternative Names: ASP-2408

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Maxygen
  • Developer Astellas Pharma
  • Class Antirheumatics; Immunoglobulin fusion proteins
  • Mechanism of Action CD28 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 01 Nov 2013 Discontinued - Phase-I for Rheumatoid arthritis in Japan (SC)
  • 01 Nov 2013 Discontinued - Phase-I for Rheumatoid arthritis in USA (IV)
  • 01 Oct 2013 Astellas Pharma completes a phase I trial in Healthy volunteers in Japan (NCT02140125)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top